Immunotherapy for Early-Stage Non–Small Cell Lung Cancer: A Practical Guide of Current Controversies

作者：William J. Phillips, Ashley Jackson, Biniam Kidane, Gerald Lim, Vishal Navani, Paul Wheatley‐Price · 发表于：Clinical Lung Cancer · 年份：2025 · DOI：10.1016/j.cllc.2025.01.006 · 被引用次数：9 · 研究领域：Lung Cancer Diagnosis and Treatment、Lung Cancer Treatments and Mutations、Lung Cancer Research Studies

The role of immunotherapy as systemic therapy for nonmetastatic non-small cell lung cancer (NSCLC) has evolved rapidly over the last decade. There are several well-conducted phase 3 clinical trials evaluating immunotherapy in the neoadjuvant, perioperative, adjuvant and nonoperative setting. In this narrative review, we summarize the data from these studies and discuss ongoing controversies in applying these data to clinical practice. These controversies relate to the value of the adjuvant component of perioperative immunotherapy, treatment of patients with PDL1 negative tumors, defining resectability, optimal use of operative versus nonoperative management, the role of stereotactic radiation therapy for very early lung cancers, and management of tumors with an oncogenic driver.